Clinical Trials Logo

Fetal Death clinical trials

View clinical trials related to Fetal Death.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT05365464 Withdrawn - Clinical trials for Recurrent Pregnancy Loss Without Current Pregnancy

HOPE Trial hCG or Progesterone Effect on Recurrent Pregnancy Loss

HOPE
Start date: May 2022
Phase: Phase 2
Study type: Interventional

Up to half of all cases of recurrent pregnancy loss are unexplained (uRPL). Evidence points towards endometriosis and progesterone resistance as an underlying cause of uRPL. Previous non-RCT studies have suggested the luteal hCG provides a useful treatment for uRPL. We propose performing a randomized controlled trial to compare mid-luteal hCG with oral progesterone to prevent early pregnancy losses. the endpoint will be ongoing pregnancy and live birth rates. Equal numbers of patients will be randomized to each group.

NCT ID: NCT02379650 Withdrawn - Miscarriage Clinical Trials

Hydroxychloroquine (HCQ) for Recurrent Pregnancy Loss

Start date: July 2016
Phase: Phase 2
Study type: Interventional

Recurrent pregnancy loss (RPL) affects 5% of couples trying to achieve parenthood. Most cases of RPL are unexplained and have no effective treatment to improve the likelihood of a pregnancy resulting in a live birth. This leads to significant patient and provider frustration and emotional stress. Hydroxychloroquine (HCQ) is a medication commonly used in pregnancy to treat autoimmune and connective tissue diseases such as systemic lupus erythematosus (SLE). This use has shown that HCQ is very safe in pregnancy. HCQ has anti-inflammatory and anti-thrombotic effects and thus may improve pregnancy outcomes in couples with unexplained RPL. Although some providers are already prescribing HCQ for unexplained RPL, a randomized controlled trial is necessary to determine the true efficacy and safety of this treatment. This study has the potential to establish support for a new treatment option for unexplained RPL.